161 related articles for article (PubMed ID: 14700625)
1. Designer gene therapy using an Escherichia coli purine nucleoside phosphorylase/prodrug system.
Bennett EM; Anand R; Allan PW; Hassan AE; Hong JS; Levasseur DN; McPherson DT; Parker WB; Secrist JA; Sorscher EJ; Townes TM; Waud WR; Ealick SE
Chem Biol; 2003 Dec; 10(12):1173-81. PubMed ID: 14700625
[TBL] [Abstract][Full Text] [Related]
2. PNP anticancer gene therapy.
Zhang Y; Parker WB; Sorscher EJ; Ealick SE
Curr Top Med Chem; 2005; 5(13):1259-74. PubMed ID: 16305530
[TBL] [Abstract][Full Text] [Related]
3. 6-Methylpurine derived sugar modified nucleosides: Synthesis and in vivo antitumor activity in D54 tumor expressing M64V-Escherichia coli purine nucleoside phosphorylase.
Hassan AEA; Abou-Elkhair RAI; Parker WB; Allan PW; Secrist JA
Eur J Med Chem; 2016 Jan; 108():616-622. PubMed ID: 26724729
[TBL] [Abstract][Full Text] [Related]
4. Design and evaluation of 5'-modified nucleoside analogs as prodrugs for an E. coli purine nucleoside phosphorylase mutant.
Parker WB; Allan PW; Ealick SE; Sorscher EJ; Hassan AE; Silamkoti AV; Fowler AT; Waud WR; Secrist JA
Nucleosides Nucleotides Nucleic Acids; 2005; 24(5-7):387-92. PubMed ID: 16247956
[TBL] [Abstract][Full Text] [Related]
5. The crystal structure of Escherichia coli purine nucleoside phosphorylase: a comparison with the human enzyme reveals a conserved topology.
Mao C; Cook WJ; Zhou M; Koszalka GW; Krenitsky TA; Ealick SE
Structure; 1997 Oct; 5(10):1373-83. PubMed ID: 9351810
[TBL] [Abstract][Full Text] [Related]
6. In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase.
Sorscher EJ; Hong JS; Allan PW; Waud WR; Parker WB
Cancer Chemother Pharmacol; 2012 Aug; 70(2):321-9. PubMed ID: 22760227
[TBL] [Abstract][Full Text] [Related]
7. Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene.
Hughes BW; Wells AH; Bebok Z; Gadi VK; Garver RI; Parker WB; Sorscher EJ
Cancer Res; 1995 Aug; 55(15):3339-45. PubMed ID: 7614469
[TBL] [Abstract][Full Text] [Related]
8. Antibiotic-mediated chemoprotection enhances adaptation of E. coli PNP for herpes simplex virus-based glioma therapy.
Bharara S; Sorscher EJ; Gillespie GY; Lindsey JR; Hong JS; Curlee KV; Allan PW; Gadi VK; Alexander SA; Secrist JA; Parker WB; Waud WR
Hum Gene Ther; 2005 Mar; 16(3):339-47. PubMed ID: 15812229
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of 2-fluoro-2'-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase.
Parker WB; Allan PW; Hassan AE; Secrist JA; Sorscher EJ; Waud WR
Cancer Gene Ther; 2003 Jan; 10(1):23-9. PubMed ID: 12489025
[TBL] [Abstract][Full Text] [Related]
10. 6-Methylpurine derived sugar modified nucleosides: Synthesis and evaluation of their substrate activity with purine nucleoside phosphorylases.
Hassan AE; Abou-Elkhair RA; Parker WB; Allan PW; Secrist JA
Bioorg Chem; 2016 Apr; 65():9-16. PubMed ID: 26745284
[TBL] [Abstract][Full Text] [Related]
11. In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase.
Parker WB; King SA; Allan PW; Bennett LL; Secrist JA; Montgomery JA; Gilbert KS; Waud WR; Wells AH; Gillespie GY; Sorscher EJ
Hum Gene Ther; 1997 Sep; 8(14):1637-44. PubMed ID: 9322865
[TBL] [Abstract][Full Text] [Related]
12. Escherichia coli purine nucleoside phosphorylase II, the product of the xapA gene.
Dandanell G; Szczepanowski RH; Kierdaszuk B; Shugar D; Bochtler M
J Mol Biol; 2005 Apr; 348(1):113-25. PubMed ID: 15808857
[TBL] [Abstract][Full Text] [Related]
13. Cell to cell contact is not required for bystander cell killing by Escherichia coli purine nucleoside phosphorylase.
Hughes BW; King SA; Allan PW; Parker WB; Sorscher EJ
J Biol Chem; 1998 Jan; 273(4):2322-8. PubMed ID: 9442077
[TBL] [Abstract][Full Text] [Related]
14. Crystallographic snapshots of ligand binding to hexameric purine nucleoside phosphorylase and kinetic studies give insight into the mechanism of catalysis.
Štefanić Z; Narczyk M; Mikleušević G; Kazazić S; Bzowska A; Luić M
Sci Rep; 2018 Oct; 8(1):15427. PubMed ID: 30337572
[TBL] [Abstract][Full Text] [Related]
15. Excellent in vivo bystander activity of fludarabine phosphate against human glioma xenografts that express the escherichia coli purine nucleoside phosphorylase gene.
Hong JS; Waud WR; Levasseur DN; Townes TM; Wen H; McPherson SA; Moore BA; Bebok Z; Allan PW; Secrist JA; Parker WB; Sorscher EJ
Cancer Res; 2004 Sep; 64(18):6610-5. PubMed ID: 15374975
[TBL] [Abstract][Full Text] [Related]
16. Efficient Fludarabine-Activating PNP From Archaea as a Guidance for Redesign the Active Site of E. Coli PNP.
Cacciapuoti G; Bagarolo ML; Martino E; Scafuri B; Marabotti A; Porcelli M
J Cell Biochem; 2016 May; 117(5):1126-35. PubMed ID: 26477689
[TBL] [Abstract][Full Text] [Related]
17. Effect of expression of adenine phosphoribosyltransferase on the in vivo anti-tumor activity of prodrugs activated by E. coli purine nucleoside phosphorylase.
Parker WB; Allan PW; Waud WR; Hong JS; Sorscher EJ
Cancer Gene Ther; 2011 Jun; 18(6):390-8. PubMed ID: 21394111
[TBL] [Abstract][Full Text] [Related]
18. Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer.
Afshar S; Asai T; Morrison SL
Mol Cancer Ther; 2009 Jan; 8(1):185-93. PubMed ID: 19139128
[TBL] [Abstract][Full Text] [Related]
19. In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells.
Gadi VK; Alexander SD; Kudlow JE; Allan P; Parker WB; Sorscher EJ
Gene Ther; 2000 Oct; 7(20):1738-43. PubMed ID: 11083495
[TBL] [Abstract][Full Text] [Related]
20. Structure of a mutant human purine nucleoside phosphorylase with the prodrug, 2-fluoro-2'-deoxyadenosine and the cytotoxic drug, 2-fluoroadenine.
Afshar S; Sawaya MR; Morrison SL
Protein Sci; 2009 May; 18(5):1107-14. PubMed ID: 19388075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
